Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2019 from OUS - Department of Cancer Immunology
31 publications found
Induction of neoantigen-reactive T cells from healthy donors
Nat Protoc, 14 (6), 1926-1943
DOI 10.1038/s41596-019-0170-6, PubMed 31101906
Resident memory CD8 T cells persist for years in human small intestine
J Exp Med, 216 (10), 2412-2426
DOI 10.1084/jem.20190414, PubMed 31337737
EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology
SLAS Discov, 24 (3), 398-413
DOI 10.1177/2472555218816276, PubMed 30616481
The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
J Immunol, 202 (5), 1397-1405
DOI 10.4049/jimmunol.1701703, PubMed 30692213
Imbalance of Genes Encoding Natural Killer Immunoglobulin-Like Receptors and Human Leukocyte Antigen in Patients With Biliary Cancer
Gastroenterology, 157 (4), 1067-1080.e9
DOI 10.1053/j.gastro.2019.06.023, PubMed 31229495
Hierarchical Normalized Completely Random Measures for Robust Graphical Modeling
Bayesian Anal, 14 (4), 1271-1301
DOI 10.1214/19-ba1153, PubMed 32431780
Correction: Ezrin-anchored PKA phosphorylates serine 369 and 373 on connexin 43 to enhance gap junction assembly, communication, and cell fusion
Biochem J, 476 (13), 1927
DOI 10.1042/BCJ-2017-0529_COR, PubMed 31266855
Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma
Front Immunol, 10, 2085
DOI 10.3389/fimmu.2019.02085, PubMed 31572357
Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency
J Allergy Clin Immunol Pract, 7 (6), 1970-1985.e4
DOI 10.1016/j.jaip.2019.02.038, PubMed 30877075
Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Lancet Neurol, 18 (5), 439-458
DOI 10.1016/S1474-4422(19)30034-1, PubMed 30871944
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study
JAMA Oncol, 5 (12), 1749-1768
DOI 10.1001/jamaoncol.2019.2996, PubMed 31560378
Remodeling of secretory lysosomes during education tunes functional potential in NK cells
Nat Commun, 10 (1), 514
DOI 10.1038/s41467-019-08384-x, PubMed 30705279
Human Germinal Center B Cells Differ from Naïve and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response
Cytometry A, 95 (4), 442-449
DOI 10.1002/cyto.a.23737, PubMed 30838773
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Cancer Immunol Res, 7 (3), 355-362
DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721
Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
Oncoimmunology, 8 (4), e1565236
DOI 10.1080/2162402X.2019.1565236, PubMed 30906659
NK cells specifically TCR-dressed to kill cancer cells
EBioMedicine, 40, 106-117
DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
Oncoimmunology, 8 (3), 1558663
DOI 10.1080/2162402X.2018.1558663, PubMed 30723591
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732
Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer
Oncogene, 38 (35), 6301-6318
DOI 10.1038/s41388-019-0879-2, PubMed 31312022
Intra-lineage Plasticity and Functional Reprogramming Maintain Natural Killer Cell Repertoire Diversity
Cell Rep, 29 (8), 2284-2294.e4
DOI 10.1016/j.celrep.2019.10.058, PubMed 31747601
Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy
Cancers (Basel), 11 (2)
DOI 10.3390/cancers11020176, PubMed 30717461
Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics
Mol Biotechnol, 61 (4), 286-303
DOI 10.1007/s12033-019-00156-8, PubMed 30729435
Targeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides
Cancers (Basel), 11 (8)
DOI 10.3390/cancers11081088, PubMed 31370273
Off-label uses of drugs for depression
Eur J Pharmacol, 865, 172732
DOI 10.1016/j.ejphar.2019.172732, PubMed 31622593
An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL
Leukemia, 34 (2), 478-487
DOI 10.1038/s41375-019-0569-7, PubMed 31471562
Carboxyl-Terminal Src Kinase Binds CD28 upon Activation and Mutes Downstream Signaling
J Immunol, 203 (4), 1055-1063
DOI 10.4049/jimmunol.1801660, PubMed 31292214
Activated dendritic cells and monocytes in HIV immunological nonresponders: HIV-induced interferon-inducible protein-10 correlates with low future CD4+ recovery
AIDS, 33 (7), 1117-1129
DOI 10.1097/QAD.0000000000002173, PubMed 30789356
FOXK1 and FOXK2 regulate aerobic glycolysis
Nature, 566 (7743), 279-283
DOI 10.1038/s41586-019-0900-5, PubMed 30700909
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750
Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy
NPJ Breast Cancer, 5, 13
DOI 10.1038/s41523-019-0108-8, PubMed 30993194